Evidence map›Paper›PMID 33623805›Full record

ArticleOpen forum infectious diseases2021

The COVID-19 Symptom to Isolation Cascade in a Latinx Community: A Call to Action.

Luis A Rubio, James Peng, Susy Rojas, Susana Rojas, Emily Crawford, Douglas Black, Jon Jacobo, Valerie Tulier-Laiwa, Christopher M Hoover, Jackie Martinez and 12 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The effectiveness of COVID-19 testing and contact tracing in a US city.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Luis A RubioDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-6548-2798
James PengDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Susy RojasLatino Task Force-COVID-19, San Francisco, California, USA.
Susana RojasLatino Task Force-COVID-19, San Francisco, California, USA.
Emily CrawfordChan Zuckerberg Biohub, San Francisco, California, USA.
Douglas BlackDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Jon JacoboLatino Task Force-COVID-19, San Francisco, California, USA.
Valerie Tulier-LaiwaLatino Task Force-COVID-19, San Francisco, California, USA.
Christopher M HooverDivision of Epidemiology and Biostatistics, University of California, Berkeley, Berkeley, California, USA.
Jackie MartinezUnidos en Salud, San Francisco, California, USA.
Diane JonesUnidos en Salud, San Francisco, California, USA.
Darpun SachdevSan Francisco Department of Public Health, San Francisco, California, USA.
Chesa CoxDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Eduardo HerreraUnidos en Salud, San Francisco, California, USA.
Rebecca ValenciaUnidos en Salud, San Francisco, California, USA.
Karla G ZuritaUnidos en Salud, San Francisco, California, USA.
Gabriel ChamieDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-5860-8081
CLIAHUB Consortium
Joe DeRisiChan Zuckerberg Biohub, San Francisco, California, USA.
Maya PetersenDivision of Epidemiology and Biostatistics, University of California, Berkeley, Berkeley, California, USA.ORCID https://orcid.org/0000-0003-4941-2041
Diane V HavlirDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0761-3136
Carina MarquezDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7622-6562
University of California, San Francisco · USUnited in Health · USUniversity of California, Berkeley · USSan Francisco Department of Public Health · US

Funding

San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

backgroundRapid coronavirus disease 2019 (COVID-19) diagnosis and isolation of infectious persons are critical to stopping forward transmission, and the care cascade framework can identify gaps in the COVID-19 response.

methodsWe described a COVID-19 symptom to isolation cascade and barriers among symptomatic persons who tested polymerase chain reaction positive for severe acute respiratory disease coronavirus 2 (SARS-CoV-2) at a low-barrier testing site serving a low-income Latinx community in San Francisco. Steps in the cascade are defined as days from symptom onset to test, test to result, and result to counseling on self-isolation. We examined SARS-CoV-2 cycle threshold (Ct) values to assess the likelihood of infectiousness on the day of testing and during missed isolation days.

resultsAmong 145 persons, 97% were Latinx and 81% had an income of <$50

conclusionsOver half of the 10-day isolation period passed by the time of disclosure, and over a fifth of people were likely outside the window of infectiousness by the time they received results. Improvements in test access and turnaround time, plus support for isolation, are needed for epidemic control of SARS-CoV-2 in highly impacted communities.

Indexed as

care cascadeCOVID-19HispanicLatinoLatinxvulnerable populations

Identifiers

PMID33623805
PMCPMC7888566
OpenAlexW3121555256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.